These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28343977)

  • 1. Sacituzumab govitecan activity in advanced breast cancer.
    Burki TK
    Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
    [No Abstract]   [Full Text] [Related]  

  • 3. Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e194. PubMed ID: 30827748
    [No Abstract]   [Full Text] [Related]  

  • 4. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 5. A closer look at sacituzumab govitecan-hziy.
    Bardia A
    Clin Adv Hematol Oncol; 2020 Nov; 18(11):715-717. PubMed ID: 33406063
    [No Abstract]   [Full Text] [Related]  

  • 6. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
    Altundag K
    Breast Cancer; 2024 Jul; 31(4):735. PubMed ID: 38647866
    [No Abstract]   [Full Text] [Related]  

  • 11. An ADC for Triple-Negative Breast Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF8. PubMed ID: 26577300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
    Kabirian R; Da Silva A
    Bull Cancer; 2022 Mar; 109(3):249-250. PubMed ID: 35094841
    [No Abstract]   [Full Text] [Related]  

  • 13. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    Pavone G; Motta L; Martorana F; Motta G; Vigneri P
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
    Bardia A
    Clin Adv Hematol Oncol; 2021 Nov; 19(11):723-725. PubMed ID: 34807017
    [No Abstract]   [Full Text] [Related]  

  • 17. Histologic subtypes in chemotherapy vs. sacituzumab sovitecan groups might affect progression-free and overall survival in metastatic triple-negative breast cancer.
    Altundag K
    J BUON; 2021; 26(3):1174-1175. PubMed ID: 34268994
    [No Abstract]   [Full Text] [Related]  

  • 18. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.